by | May 24, 2024 | Publications
J Nanobiotechnology. 2024 May 23;22(1):279. doi: 10.1186/s12951-024-02512-6. ABSTRACT BACKGROUND: BCMA-directed autologous chimeric antigen receptor T (CAR-T) cells have shown excellent clinical efficacy in relapsed or refractory multiple myeloma (RRMM), however, the...
by | May 23, 2024 | Publications
Cureus. 2024 Apr 22;16(4):e58736. doi: 10.7759/cureus.58736. eCollection 2024 Apr. ABSTRACT Cord compression is not a known complication of sternal puncture. We report the case of a patient with a history of multiple myeloma who presented acute onset paraplegia...
by | May 23, 2024 | Publications
Cell Rep Med. 2024 May 17:101584. doi: 10.1016/j.xcrm.2024.101584. Online ahead of print. ABSTRACT Iberdomide is a potent cereblon E3 ligase modulator (CELMoD agent) with promising efficacy and safety as a monotherapy or in combination with other therapies in patients...
by | May 23, 2024 | Publications
Int J Hematol. 2024 May 23. doi: 10.1007/s12185-024-03794-0. Online ahead of print. ABSTRACT Currently available chimeric antigen receptor (CAR)-engineered T-cell therapies targeting B-cell maturation antigen (BCMA), namely, idecabtagene vicleucel and ciltacabtagene...
by | May 23, 2024 | Publications
Cell Rep Med. 2024 May 15:101571. doi: 10.1016/j.xcrm.2024.101571. Online ahead of print. ABSTRACT Iberdomide is a next-generation cereblon (CRBN)-modulating agent in the clinical development in multiple myeloma (MM). The analysis of biomarker samples from...
by | May 22, 2024 | Publications
Blood Adv. 2024 May 22:bloodadvances.2023012470. doi: 10.1182/bloodadvances.2023012470. Online ahead of print. ABSTRACT BCMA-targeting CAR-T cells used in multiple myeloma (MM) are rapidly becoming a mainstay in the treatment of relapsed/refractory (RR) disease, and...
